Search Results
Your search for ,New matches 16916 pages
Showing 3551 - 3600Dual-Targeted Therapy Improves Outcomes vs Chemotherapy for Some Pediatric Patients With Low-Grade Glioma
The all-oral combination of dabrafenib plus trametinib—two targeted therapies—significantly improved the overall response rate vs standard-of-care chemotherapy with carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas. The clinical benefit rate...
EAU22: New Research Supports Risk-Based Prostate Cancer Screening
Data from the world’s largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening program for the disease, said researchers. In 2009, the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that screening can reduce...
New Consensus-Based Guidance on Managing Cancer Pain in Patients With Opioid Use Disorder or Opioid Misuse
Opioids are a cornerstone of cancer pain management, but there is a lack of consensus on how to treat pain patients with cancer who also have struggled with opioid use disorder or prescription opioid misuse. In a study published by Fitzgerald Jones et al in JAMA Oncology, researchers outlined...
Lisocabtagene Maraleucel as Second-Line Treatment for Relapsed or Refractory Large B-Cell Lymphoma: TRANSFORM Trial
As reported in The Lancet by Manali Kamdar, MD, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage immunochemotherapy followed by autologous hematopoietic...
Food Interventions and Cancer Treatment Completion Rates Among Food-Insecure Patients in New York City
In a study reported in the Journal of Clinical Oncology, Francesca Gany, MD, MS, and colleagues found that food interventions were associated with high rates of cancer treatment completion rates among food-insecure patients in New York City (NYC). Study Details The study included 117 patients with...
Study Seeks to Determine if HER2-Low Breast Cancer Is a Distinct Biological and Prognostic Subtype of Disease
The treatment of breast cancer abounding in the protein HER2 was revolutionized with the introduction of drugs like trastuzumab that target the protein. When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they...
NEJM Editors Publish Opinion Following Dobbs v Jackson Decision
On June 24, the editors of The New England Journal of Medicine (NEJM) published an editorial online in response to the U.S. Supreme Court (SCOTUS) decision in the case of Dobbs v Jackson Women’s Health Organization. The Court held in a vote of 5 to 4 that the Constitution of the United States does...
Study Finds COVID-19 Vaccines Are Safe for Patients Treated With Immune Checkpoint Inhibitors for Lung Cancer
Patients with cancer have received priority status to receive COVID-19 vaccinations, but limited data are available regarding the safety and efficacy of the vaccines for patients treated with immune checkpoint inhibitors for lung cancer. Now, a new study published by Hibino et al in the Journal of...
Children’s Cancer Cause Accepting Applications Through July 31 for 2022 Survivorship Champion’s Prize
The national advocacy group Children’s Cancer Cause, which plays a leadership role in advocacy and training on national issues affecting childhood cancer, has established an annual $10,000 award, the Survivorship Champion’s Prize, to be presented to a group, program, or institution making...
18 Million Cancer Survivors in the United States, New Report Shows
A new report led by researchers at the American Cancer Society (ACS) in collaboration with the National Cancer Institute (NCI) shows more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were living in the United States as of January 1, 2022, with a...
Early Transplant With Triplet Therapy May Delay Progression of Myeloma, but Individualized Approach Recommended
In the phase III DETERMINATION trial, progression-free survival was significantly improved with triplet induction therapy and early transplantation in newly diagnosed patients with multiple myeloma, but overall survival at 5 years was similar to the nontransplant approach.1 The findings were...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare and...
ASCO Statement on Supreme Court Decision in Dobbs v Jackson Women’s Health
On June 27, ASCO released a statement on the recent ruling in Dobbs v Jackson Women’s Health. ASCO is committed to the delivery of medically appropriate, equitable, evidence-based cancer care. For patients of child-bearing age, a cancer diagnosis raises medical considerations around pregnancy and...
Raising the Bar: Rethinking the Accelerated Drug Approval Process
Our growing knowledge of the molecular and genomic drivers of cancer has translated into a robust pipeline of promising anticancer agents. However, bringing new drugs from the lab to the patient with cancer can be frustratingly slow. To that end, the accelerated approval system was created by the...
Chemicals in Personal Care Products May Increase Breast Cancer Risk in Black Women
The group of compounds called parabens, which are found in widely used hair and personal care products, may increase breast cancer risk in Black women—more so than in White women—according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. One in eight women in the United...
Study Links Diabetes and Worse Outcomes in Long-Term Survivors of Metastatic Breast Cancer
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a new study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. This is the first study to specifically examine the ...
AI May Be Used to Identify Benign Thyroid Nodules and Reduce Unnecessary Biopsies
Artificial intelligence (AI) may be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. Thyroid nodules are very...
Circulating Tumor Cells in the Staging of Newly Diagnosed Patients With Transplant-Eligible Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Garcés et al found that increasing levels of circulating tumor cells (CTCs) at diagnosis were associated with poorer outcomes in newly diagnosed patients with transplant-eligible multiple myeloma, and that inclusion of CTCs in a risk model...
Immunotherapy Has Given Me Back My Life
Hearing the words “You have cancer” is a devastating blow, especially when the biggest health issues you’ve had to contend with over more than 6 decades are common colds and knee and hip replacements. But in 2017, the symptoms I thought were from a lingering summer cold drove me to seek medical...
History of Radiation Oncology in the United States
Radiation therapy has long been one of the three pillars of cancer therapy—surgery, chemotherapy, and radiotherapy—only recently joined by what is widely considered a fourth pillar, immunotherapy. In part 1 of this two-part report, we trace the beginnings of radiation oncology in the United...
ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...
Ariela L. Marshall, MD, Advocates for Equity and Reproductive Health in the Hematology-Oncology Community
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, FACP, spoke with Ariela L. Marshall, MD, Director, Women’s Hemostasis and Thrombosis Program at Penn Medicine. Along with her clinical and research activities, Dr. Marshall is also an advocate for women’s health and equity in ...
Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors
On June 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval for dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with a BRAF V600E mutation whose disease...
FDA Denies Authorization to Market JUUL Products
On June 23, the U.S. Food and Drug Administration (FDA) issued marketing denial orders (MDOs) to JUUL Labs Inc for all of their products currently marketed in the United States. As a result, the company must stop selling and distributing these products. In addition, those currently on the U.S....
Cancer and War in Ukraine: How the World Can Help Win This Battle
In Ukraine, with a population of about 44 million, there are more than 1.3 million patients with cancer. Approximately 160,000 new cases of cancer are diagnosed each year.1 In almost every region, there are local cancer centers; specialized oncologic centers are located in large cities. In Kyiv,...
Study Predicts Cancer Cases and Deaths in Africa Could Double by 2040
Cancer cases and deaths are expected to double in Africa over the next 2 decades, according to findings from a study published by Sharma et al in Frontiers in Medicine. The study also revealed that the region lacks sufficient health-care resources and infrastructure to handle this growing cancer...
Nivolumab/Cabozantinib vs Sunitinib in First-Line Treatment for Advanced RCC: Overall Survival Analysis of CheckMate 9ER Trial
As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, the protocol-defined final overall survival analysis of the phase III CheckMate 9ER trial showed a significant benefit with nivolumab/cabozantinib vs sunitinib in previously untreated patients with advanced renal cell...
Invest in the Unexpected: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
The National Institutes of Health (NIH) now stands as the largest single public funder of biomedical research in the world.1 The FY2022 Consolidated Appropriations Act (H.R. 2471), signed into law in March, increases biomedical research funding by nearly 5%, and it provides a total of $45 billion...
Interventions Needed to Improve Data Collection on Sexual Orientation and Gender Identity in Oncology Practice, Survey Finds
Recently, a new ASCO study,1 published in JCO Oncology Practice, found that among respondents participating in the survey, most oncology practices do not systematically collect data related to sexual orientation and gender identity (SOGI). The study points to the need to increase understanding...
ASCO Relaunches Survivorship Compendium With New Features and Resources
ASCO has made new resources available through its refreshed Survivorship Compendium—an online library of practice tools designed and curated to help oncologists develop high-quality, equitable cancer survivorship care programs and improve existing programs for patients who have completed their...
ASCO’s CancerLinQ and Count Me In Collaborate to Empower Patient Participation in Clinical Cancer Research
ASCO’s CancerLinQ® and Count Me In recently announced a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ—a real-world oncology data technology platform developed by...
American Cancer Society Investigators Present Studies on COVID-19 Pandemic, Racial/Ethnic Disparities, and Coverage for Genomic Testing
Investigators at the American Cancer Society presented results of several studies during poster sessions at the 2022 ASCO Annual Meeting. Summaries of a few of these studies are provided here. COVID-19 and Cancer Mortality According to a new study led by researchers at the American Cancer Society,...
Expert Point of View: Kimmie Ng, MD, MPH
The study’s invited discussant was Kimmie Ng, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Co-Director of the Colon and Rectal Cancer Center at Dana-Farber Cancer Institute, Boston. “Neoadjuvant dostarlimab-gxly for 6 months represents a promising new treatment for...
100% Complete Response Rate in 14 Patients With Rectal Cancer Treated With Neoadjuvant Dostarlimab-gxly
In a study of 18 patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of neoadjuvant treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses in 100% of the study’s first 14 patients.1 These results were presented at the 2022...
Expert Point of View: Patricia LoRusso, DO, PhD
Invited discussant Patricia LoRusso, DO, PhD, of Yale School of Medicine, said to the assembled audience at the 2022 ASCO Annual Meeting: “I see you are as excited about these data as I am,” after the applause ended following Dr. Modi’s presentation. “I want to thank our colleagues for helping to...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
CheckMate 274: Adjuvant Immunotherapy Improves Disease-Free Survival in Metastatic Urothelial Cancer
Adjuvant nivolumab could become the standard of care for patients with metastatic bladder cancer, according to data presented at the American Urological Association (AUA) 2022 Annual Meeting.1 With longer follow-up, the results of the phase III CheckMate 274 trial showed that treatment with the...
Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation
New research published by Zeng et al in JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical trial findings that show adjuvant hormone therapy–related hot flashes predict better treatment outcomes among patients with estrogen receptor–positive breast cancer. The...
Study Links Sugar-Sweetened Beverage Consumption and Liver Cancer Risk
A study of more than 90,000 postmenopausal women found that those who consumed at least one sugar-sweetened beverage daily faced a 78% higher risk of developing liver cancer compared with people who consumed less than three servings per month of such beverages. These findings were presented by Zhao ...
Study Examines How Diet Quality May Affect Breast Cancer Risk
Research shows that what we eat may influence our cancer risk, but it’s not always clear which foods or dietary patterns are best for cancer prevention. Results from a new study presented by Shah et al during Nutrition 2022 Live Online, the annual meeting of the American Society for Nutrition,...
Factors That May Predict Response to the Addition of Bevacizumab to Front-Line Chemotherapy in Patients With Endometrial Cancer
In an analysis from an NRG Oncology/Gynecologic Oncology Group phase II study (GOG-86P) reported in the Journal of Clinical Oncology, Thiel et al looked at outcomes in patients with advanced endometrial cancer treated with bevacizumab added to front-line chemotherapy. The investigators found that...
Ovarian Cancer: First-Line Every-3-Week Carboplatin/Paclitaxel vs Weekly Dose-Dense Regimens
As reported in The Lancet Oncology by Andrew R. Clamp, PhD, and colleagues, no significant differences in overall survival or updated progression-free survival were found with first-line treatment with weekly dose-dense regimens of carboplatin/paclitaxel vs every-3-week carboplatin/paclitaxel in...
New Perspective Shows Higher Breast Cancer Mortality for Black Women Emerged 40 Years Ago
A new perspective piece authored by researchers from the American Cancer Society and The University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality among Black women as compared to White women began in the United States in the 1980s. At that time,...
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer in Persons With HIV
In the phase III ANCHOR study reported in The New England Journal of Medicine, Palefsky et al found that treatment of high-grade squamous intraepithelial lesions was successful in preventing anal cancer vs active monitoring in persons infected with HIV. Study Details In the multicenter trial, 4,446 ...
Four New Teams Receive $100M to Take on Cancer's Toughest Challenges
Representing a total investment of $100 million, the following teams are the first to be funded through the partnership between Cancer Research UK and the National Cancer Institute in the United States. These teams join the Cancer Grand Challenges community, which now unites more than 700...
Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki
Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).
An Oncology Surgeon Leads Mexico’s Melanoma Program
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with surgical oncologist Héctor Martínez-Said, MD, of the Melanoma Clinic at NCI Mexico. Dr. Martínez-Said’s maternal grandfather was part of a Lebanese immigration movement...
Study Finds Diagnostic Mammography Performance Varies Across Racial and Ethnic Groups
The disparities in female breast cancer incidence and mortality among racial and ethnic groups is well documented. Studies show that while Black women have a lower incidence of breast cancer compared with White women, they are 41% more likely to die from the disease than White women. Breast cancer...
Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal
Most men with low-risk prostate tumors now opt for active surveillance, but overtreatment remains a problem, according to data presented during the 2022 American Urological Association (AUA) Annual Meeting.1 A retrospective analysis of more than 20,000 patients with low-risk prostate cancer showed...
Looking Back at Telemedicine During the COVID-19 Era: Lessons Learned and Disparities Identified
Telemedicine stepped up to the plate when the COVID-19 pandemic swept the globe. Oncology providers—and practitioners in all specialties—had to rapidly adapt to a telemedicine format when face-to-face visits were severely limited. This scenario had its benefits for both patients and providers (and...
